ADAM29

Summary

ADAM29 (ADAM metallopeptidase domain 29, HGNC:207) is a protein-coding gene on chromosome 4q34.1, encoding Disintegrin and metalloproteinase domain-containing protein 29 (Q9UKF5). May be involved in spermatogenesis and fertilization.

This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. The protein encoded by this gene is highly expressed in testis and may be involved in human spermatogenesis. Alternative splicing results in multiple transcript variants that encode the same protein.

Source: NCBI Gene 11086 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 135 total — 4 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_014269

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:207
Approved symbol	ADAM29
Name	ADAM metallopeptidase domain 29
Location	4q34.1
Locus type	gene with protein product
Status	Approved
Aliases	svph1, CT73
Ensembl gene	ENSG00000168594
Ensembl biotype	protein_coding
OMIM	604778
Entrez	11086

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 9 protein_coding, 4 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000359240, ENST00000404450, ENST00000445694, ENST00000502305, ENST00000502940, ENST00000505141, ENST00000507652, ENST00000507969, ENST00000510280, ENST00000513477, ENST00000514159, ENST00000515538, ENST00000615367, ENST00000618444

RefSeq mRNA: 7 — MANE Select: NM_014269 NM_001130703, NM_001130704, NM_001130705, NM_001278125, NM_001278126, NM_001278127, NM_014269

CCDS: CCDS3823

Canonical transcript exons

ENST00000359240 — 5 exons

Exon	Start	End
ENSE00001402920	174936933	174937013
ENSE00001405560	174930986	174931174
ENSE00001479503	174920687	174920792
ENSE00001559522	174918358	174918471
ENSE00003826702	174975346	174978180

Expression profiles

Bgee: expression breadth broad, 89 present calls, max score 93.88.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0773 / max 65.8584, expressed in 5 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
50688	0.0358	3
50686	0.0101	3
50683	0.0090	3
50689	0.0077	3
50685	0.0076	3
50687	0.0071	3

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	93.88	gold quality
male germ cell	CL:0000015	91.49	gold quality
left testis	UBERON:0004533	90.82	gold quality
right testis	UBERON:0004534	90.20	gold quality
testis	UBERON:0000473	87.99	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.51	gold quality
endothelial cell	CL:0000115	73.89	gold quality
adult organism	UBERON:0007023	71.54	gold quality
buccal mucosa cell	CL:0002336	70.84	silver quality
olfactory bulb	UBERON:0002264	66.36	gold quality
superficial temporal artery	UBERON:0001614	65.58	gold quality
epithelium of nasopharynx	UBERON:0001951	62.85	gold quality
gingival epithelium	UBERON:0001949	62.59	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	62.37	gold quality
cerebellar vermis	UBERON:0004720	62.31	gold quality
diaphragm	UBERON:0001103	61.71	gold quality
parotid gland	UBERON:0001831	60.23	gold quality
lower lobe of lung	UBERON:0008949	59.63	silver quality
gluteal muscle	UBERON:0002000	59.14	gold quality
triceps brachii	UBERON:0001509	59.02	gold quality
vastus lateralis	UBERON:0001379	58.90	gold quality
quadriceps femoris	UBERON:0001377	58.89	gold quality
gingiva	UBERON:0001828	58.88	gold quality
germinal epithelium of ovary	UBERON:0001304	58.85	gold quality
upper leg skin	UBERON:0004262	58.29	silver quality
mucosa of paranasal sinus	UBERON:0005030	58.28	gold quality
islet of Langerhans	UBERON:0000006	58.26	gold quality
amniotic fluid	UBERON:0000173	58.06	gold quality
biceps brachii	UBERON:0001507	58.02	gold quality
secondary oocyte	CL:0000655	57.83	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.89
E-CURD-53	no	64.94

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting ADAM29, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-582-5P	99.47	70.79	2635
HSA-MIR-6506-5P	99.04	65.66	1386
HSA-MIR-330-5P	98.73	67.63	1788
HSA-MIR-619-5P	98.57	64.97	1988
HSA-MIR-4782-5P	98.35	69.33	1474
HSA-MIR-5706	98.35	69.33	1463
HSA-MIR-326	98.25	66.44	1565
HSA-MIR-204-3P	97.80	66.84	1656
HSA-MIR-1255B-2-3P	97.80	67.04	880
HSA-MIR-4646-5P	97.70	66.84	1692
HSA-MIR-4314	97.50	67.30	1369
HSA-MIR-3192-5P	96.98	65.76	1926
HSA-MIR-514A-5P	96.94	65.49	801
HSA-MIR-597-5P	96.82	67.57	732
HSA-MIR-563	96.26	66.13	450
HSA-MIR-4522	95.76	66.23	742
HSA-MIR-380-5P	95.68	67.32	512

Literature-anchored findings (GeneRIF, showing 5)

• quantification of LPL and ADAM29 gene expression is a strong prognostic indicator in CLL, providing better prognostic assessment than ZAP-70 in advanced stages of the disease (PMID:15802535)
• Results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies. (PMID:19340428)
• mutated ADAM27 and ADAM7 genes could play a role in melanoma progression. (PMID:21618342)
• PCMC expression of ADAM29, FLRT2, and SLC18A3 could be assessed as part of a routine screen to help identify individuals at risk of severe Obstructive sleep apnea in Asian populations (PMID:24732660)
• Increased transcript expression of ADAM29 was observed in breast cancer tissues compared to normal ones. The expression of ADAM29 and its mutations in different domains significantly influenced proliferation, migration and invasion of breast cancer cells in vitro. (PMID:26977022)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	adam10b	ENSDARG00000015502
danio_rerio	adam10a	ENSDARG00000053468
danio_rerio	adam9b	ENSDARG00000057138
danio_rerio	si:ch1073-396h14.1	ENSDARG00000057590
mus_musculus	Adam29	ENSMUSG00000046258
drosophila_melanogaster	mmd	FBGN0259110
drosophila_melanogaster	kuz	FBGN0259984
caenorhabditis_elegans	sup-17	WBGENE00006324
caenorhabditis_elegans		WBGENE00006804

Paralogs (20): ADAM22 (ENSG00000008277), ADAM28 (ENSG00000042980), ADAM7 (ENSG00000069206), ADAM11 (ENSG00000073670), ADAM2 (ENSG00000104755), ADAM23 (ENSG00000114948), ADAM20 (ENSG00000134007), ADAMDEC1 (ENSG00000134028), ADAM30 (ENSG00000134249), ADAM19 (ENSG00000135074), ADAM10 (ENSG00000137845), ADAM21 (ENSG00000139985), ADAM15 (ENSG00000143537), ADAM12 (ENSG00000148848), ADAM33 (ENSG00000149451), ADAM8 (ENSG00000151651), ADAM17 (ENSG00000151694), ADAM9 (ENSG00000168615), ADAM18 (ENSG00000168619), ADAM32 (ENSG00000197140)

Protein

Protein identifiers

Disintegrin and metalloproteinase domain-containing protein 29 — Q9UKF5 (reviewed: Q9UKF5)

Alternative names: Cancer/testis antigen 73

All UniProt accessions (5): Q9UKF5, A0A140VJD8, D6RBU0, D6RHU0, D6RIU9

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in spermatogenesis and fertilization. Seems to be a non catalytic metalloprotease-like protein.

Subcellular location. Membrane.

Tissue specificity. Expressed specifically in testes.

Disease relevance. Has been found to be frequently mutated in melanoma. ADAM7 mutations may play a role in melanoma progression and metastasis.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9UKF5-1	Alpha	yes
Q9UKF5-2	Beta
Q9UKF5-3	Gamma

RefSeq proteins (7): NP_001124175, NP_001124176, NP_001124177, NP_001265054, NP_001265055, NP_001265056, NP_055084* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001590	Peptidase_M12B	Domain
IPR001762	Disintegrin_dom	Domain
IPR002870	Peptidase_M12B_N	Domain
IPR006586	ADAM_Cys-rich	Domain
IPR018358	Disintegrin_CS	Conserved_site
IPR024079	MetalloPept_cat_dom_sf	Homologous_superfamily
IPR034027	Reprolysin_adamalysin	Domain
IPR036436	Disintegrin_dom_sf	Homologous_superfamily

Pfam: PF00200, PF01421, PF01562, PF08516

UniProt features (64 total): sequence variant 17, repeat 9, glycosylation site 9, disulfide bond 7, sequence conflict 6, splice variant 3, domain 3, region of interest 2, compositionally biased region 2, topological domain 2, signal peptide 1, propeptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UKF5-F1	77.07	0.50

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (7): 307–384, 347–369, 349–354, 455–475, 625–636, 630–642, 644–653

Glycosylation sites (9): 217, 320, 368, 428, 469, 538, 545, 558, 564

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 51 (showing top): GOMF_METALLOPEPTIDASE_ACTIVITY, XU_GH1_AUTOCRINE_TARGETS_UP, chr4q34, GOCC_CELL_SURFACE, GOBP_MALE_GAMETE_GENERATION, HUTTMANN_B_CLL_POOR_SURVIVAL_DN, GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT, GOBP_SEX_DIFFERENTIATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOBP_MALE_SEX_DIFFERENTIATION, GOBP_DEVELOPMENT_OF_PRIMARY_SEXUAL_CHARACTERISTICS, GOCC_SIDE_OF_MEMBRANE, GOBP_PROTEOLYSIS, GOCC_PLASMA_MEMBRANE_REGION, GOMF_PEPTIDASE_ACTIVITY

GO Biological Process (3): proteolysis (GO:0006508), spermatogenesis (GO:0007283), male gonad development (GO:0008584)

GO Molecular Function (3): metalloendopeptidase activity (GO:0004222), metallopeptidase activity (GO:0008237), metal ion binding (GO:0046872)

GO Cellular Component (4): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), sperm head plasma membrane (GO:1990913), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein metabolic process	1
developmental process involved in reproduction	1
male gamete generation	1
gonad development	1
development of primary male sexual characteristics	1
endopeptidase activity	1
metallopeptidase activity	1
peptidase activity	1
cation binding	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
sperm head	1
sperm plasma membrane	1
plasma membrane region	1
cellular anatomical structure	1

Protein interactions and networks

STRING

594 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ADAM29	FAM135B	Q49AJ0	663
ADAM29	XAGE1B	Q9HD64	557
ADAM29	CCDC54	Q8NEL0	537
ADAM29	MAGEC1	O60732	487
ADAM29	SEPTIN10	Q9P0V9	400
ADAM29	PRSS54	Q6PEW0	397
ADAM29	TEX55	Q96M34	385
ADAM29	CIMIP2A	Q6J272	379
ADAM29	MISFA	A0A0U1RRN3	375
ADAM29	FAT2	Q9NYQ8	369
ADAM29	ZNF354C	Q86Y25	364
ADAM29	TRIML1	Q8N9V2	356
ADAM29	TOX3	O15405	348
ADAM29	ZNF750	Q32MQ0	348
ADAM29	FAT1	Q14517	322

IntAct

2 interactions, top by confidence:

A	B	Type	Score
ADAM29	PPID	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (1): PPID (Affinity Capture-MS)

ESM2 similar proteins: A0A2K5V015, A1YIY0, A8MUZ8, A8MWA4, B8JI71, O08569, P01133, P0DJ43, P14370, P14585, P17630, P19070, P48357, P82279, P97435, Q07444, Q0D2K5, Q28066, Q28660, Q29RU2, Q4KUS1, Q5G872, Q5R6R1, Q5RCW9, Q5T1H1, Q5UKY4, Q5Z5Q3, Q60736, Q63515, Q63722, Q6DFV8, Q6GMZ9, Q6V0K7, Q6ZN79, Q7TSY4, Q811Q4, Q8N2E2, Q8VHS2, Q90Y54, Q95MI4

Diamond homologs: C5FUK3, C5H5D1, C5H5D3, C5H5D5, C5H5D6, D4B1G0, D4DCV9, O14672, O35598, O42596, O73795, O75077, O75078, O77633, O88839, O93517, O93518, O93523, P0C6E3, P0C6R9, P0DJ87, P0DM87, P17497, P83912, Q076D1, Q0NZX7, Q0NZX9, Q0NZY0, Q10741, Q10743, Q13443, Q13444, Q2LD49, Q4JCS0, Q4WQ08, Q60472, Q698K8, Q8AWI5, Q8AWX7, Q8JIY1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

135 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	1
Uncertain significance	108
Likely benign	20
Benign	0

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
3148912	GRCh37/hg19 4q34.1-34.3(chr4:172781617-182798652)x3	Pathogenic
59508	GRCh38/hg38 4q34.1-34.3(chr4:171851295-178772816)x1	Pathogenic
59512	GRCh38/hg38 4q34.1-35.1(chr4:174080892-183195538)x1	Pathogenic
635933	Single allele	Pathogenic
2685134	GRCh37/hg19 4q33-35.1(chr4:171476330-184998011)x1	Likely pathogenic

SpliceAI

931 predictions. Top by Δscore:

Variant	Effect	Δscore
4:174975281:T:A	acceptor_gain	0.9800
4:174975344:A:AG	acceptor_gain	0.9800
4:174975345:G:GG	acceptor_gain	0.9800
4:174975345:GT:G	acceptor_gain	0.9800
4:174975338:A:AG	acceptor_gain	0.9700
4:174975345:GTGCT:G	acceptor_gain	0.9700
4:174975344:AGT:A	acceptor_gain	0.9600
4:174975345:GTG:G	acceptor_gain	0.9600
4:174918469:C:T	donor_gain	0.9500
4:174975279:ACT:A	acceptor_gain	0.9500
4:174975342:ATAGT:A	acceptor_gain	0.9500
4:174975343:TAGT:T	acceptor_loss	0.9500
4:174975344:A:G	acceptor_loss	0.9500
4:174975345:G:GA	acceptor_loss	0.9500
4:174975339:C:G	acceptor_gain	0.9400
4:174975343:T:G	acceptor_gain	0.9400
4:174955852:G:GT	acceptor_gain	0.9300
4:174975345:GTGC:G	acceptor_gain	0.9300
4:174975279:ACTG:A	acceptor_gain	0.9200
4:174975341:TATAG:T	acceptor_gain	0.9200
4:174975343:TAGTG:T	acceptor_gain	0.9200
4:174975342:ATAG:A	acceptor_gain	0.9000
4:174975344:AGTG:A	acceptor_gain	0.9000
4:174918386:GTGGT:G	donor_gain	0.8800
4:174920793:G:GG	donor_gain	0.8600
4:174975282:G:A	acceptor_gain	0.8600
4:174918479:C:G	donor_gain	0.8500
4:174929563:G:GT	donor_gain	0.8500
4:174934836:C:G	donor_gain	0.8500
4:174936931:A:AG	acceptor_gain	0.8500

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS10000224 (4:174955002 A>C), RS10000310 (4:174951341 G>A,C,T), RS1000038176 (4:174960846 T>C), RS1000075582 (4:174946266 A>T), RS1000095813 (4:174921934 C>T), RS10001087 (4:174959340 T>C), RS1000111476 (4:174939057 A>G), RS1000163519 (4:174923247 G>A), RS10001808 (4:174960154 T>C), RS1000191284 (4:174968902 C>A,G), RS1000213806 (4:174932391 C>T), RS1000261206 (4:174922771 C>T), RS10002932 (4:174964426 C>T), RS1000360120 (4:174972320 A>G), RS1000368825 (4:174926793 T>A)

Disease associations

OMIM: gene MIM:604778 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001937_54	Breast cancer	4.000000e-16
GCST003075_118	Cognitive decline rate in late mild cognitive impairment	3.000000e-11
GCST003075_119	Cognitive decline rate in late mild cognitive impairment	3.000000e-08
GCST003075_37	Cognitive decline rate in late mild cognitive impairment	4.000000e-08
GCST003075_88	Cognitive decline rate in late mild cognitive impairment	6.000000e-11
GCST004988_40	Breast cancer	2.000000e-25
GCST006218_88	Erosive tooth wear (severe vs non-severe)	2.000000e-07
GCST006226_13	Erosive tooth wear (severe vs none or mild)	5.000000e-06
GCST012305_7	Major depressive disorder x sex interaction	4.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007710	cognitive decline measurement
EFO:0008343	sex interaction measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — M12: Astacin/Adamalysin

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
butyraldehyde	increases expression	1
CGP 52608	affects binding, increases reaction	1
Arsenic Trioxide	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cadmium	decreases expression, increases abundance	1
Tetrachlorodibenzodioxin	decreases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	decreases expression, increases abundance	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice